Multimedia content
- Images (3)
- Table 1: Products subject of WHO Medical Product Alert N°5/2021
- Table 2: Photographs of products subject of WHO Medical Product Alert N°5/2021 (1)
- Table 2: Photographs of products subject of WHO Medical Product Alert N°5/2021 (2)
- All (3)
Coronavirus – Africa: Medical Product Alert N°5/2021: Falsified COVISHIELD vaccine
Falsified COVISHIELD vaccine identified in the WHO regions of Africa and South- East Asia
Falsified COVID-19 vaccines pose a serious risk to global public health and place an additional burden on vulnerable populations and health systems
Alert Summary
This WHO Medical Product Alert refers to falsified COVISHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccines (Recombinant)) identified in the WHO African Region, and the WHO South-East Asia Region. The falsified products were reported to WHO in July and August 2021. The genuine manufacturer of COVISHIELD (Serum Institute of India Pvt. Ltd.) has confirmed that the products listed in this alert are falsified. These falsified products have been reported at the patient level in Uganda and India.
Genuine COVISHIELD vaccine is indicated for active immunisation of individuals 18 years or older for the prevention of coronavirus disease caused by the SARS-CoV-2 virus. The use of genuine COVID-19 vaccines should be in accordance with official guidance from national regulatory authorities.
Falsified COVID-19 vaccines pose a serious risk to global public health and place an additional burden on vulnerable populations and health systems. It is important to detect and remove these falsified products from circulation to prevent harm to patients.
The products identified in this alert are confirmed as falsified on the basis that they deliberately/ fraudulently misrepresent their identity, composition or source:
- Batch 4121Z040 - the expiry date (10.08.2021) on this product is falsified
- COVISHIELD 2ml - the genuine manufacturer does not produce COVISHIELD in 2ml (4 doses).
Advice to regulatory authorities and the public
WHO requests increased vigilance within the supply chains of countries and regions likely to be affected by these falsified products. Increased vigilance should include hospitals, clinics, health centers, wholesalers, distributors, pharmacies, and any other suppliers of medical products.
All medical products must be obtained from authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked. Seek advice from a healthcare professional in case of doubt.
If you are in possession of the above products, please do not use them.
If you have used these products, or you suffered an adverse reaction/event having used these products, you are advised to seek immediate medical advice from a qualified healthcare professional and to report the incident to the National Regulatory Authorities/National Pharmacovigilance Centre.
National regulatory / health authorities are advised to immediately notify WHO if these falsified products are
discovered in their country. If you have any information concerning the manufacture, distribution, or supply of
these products, please contact rapidalert@who.int
Distributed by APO Group on behalf of World Health Organization (WHO).
Table 1: Products subject of WHO Medical Product Alert N°5/2021
Table 2: Photographs of products subject of WHO Medical Product Alert N°5/2021 (1)
Table 2: Photographs of products subject of WHO Medical Product Alert N°5/2021 (2)